Drug comparisons
Galcanezumab vs Lasmiditan
Compare Galcanezumab (Emgality) and Lasmiditan (Reyvow) for migraine treatment. Galcanezumab is a preventive monoclonal antibody targeting CGRP, while Lasmiditan is an acute oral medication acting on 5-HT1F receptors. Choose based on your migraine pattern - frequent for galcanezumab, acute attacks for lasmiditan. Consult your doctor for personalized advice.
No comparison dimensions are available for this page.
Clinical context
Patients deciding between a preventive CGRP monoclonal antibody and an acute oral 5-HT1F receptor agonist for migraine management.
Bottom line
Both Galcanezumab and Lasmiditan are effective migraine treatments but serve different purposes, with galcanezumab for prevention and lasmiditan for acute attacks.
All medication comparisons